MedDRA preferred term · a mistake in giving the product

Product administration error: adverse event reports recording this term

19,697 reports to FDA record it, 2006–2026; 0.1% of the database.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

19,697
reports recording the term: 0.1% of all reports; 2,081
reports, 12 months to June 2026: 2,022 in the 12 months before; 40.8%
marked serious by the reporter: 57.4% across all reports; 3.9%
record death among outcomes, as reported: 9.1% across all reports

"Product administration error" (in plain words, a mistake in giving the product) is a MedDRA preferred term recorded in 19,697 adverse event reports received by FDA, 0.1% of the database, from March 2006 to June 2026. The term is chosen by whoever codes the report to match what the reporter described.

2,081 reports recorded it in the 12 months to June 2026, close to the 2,022 of the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Of reports recording this term, 40.8% are marked serious, 3.9% include death among the outcomes and 21.5% include hospitalisation, as reported.

The drugs listed most often as suspect products in those reports are Makena, Repatha and Oxervate. That order mostly follows how many reports each drug has overall; the table also gives the term's share within each drug's own reports. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Drugs listed as suspect products in these reports

Drug	Class	Reports with this term	Share of the drug's own reports
Makena	—	969	4.3%
Repatha	PCSK9 inhibitor	642	0.4%
Oxervate	—	616	5.1%
Eligard	Gonadotropin releasing hormone receptor agonist	559	1.3%
Humira	—	546	0.1%
Daytrana	Central nervous system stimulant	381	2.8%
Filspari	Angiotensin 2 receptor blocker	321	5.7%
Benicar	Angiotensin 2 receptor blocker	306	3.7%
Vivitrol	—	237	0.9%
Cosentyx	Interleukin-17A antagonist	230	0.2%
Benicar HCT	Thiazide diuretic	219	4.4%
Acetaminophen	Nonsteroidal anti-inflammatory drug	211	0.2%
Aspirin	Nonsteroidal anti-inflammatory drug	203	0.3%
Clozapine	Atypical antipsychotic	183	0.3%
Metformin	Biguanide	163	0.2%
Enbrel	Tumor necrosis factor blocker	160	0%
Ibuprofen	Nonsteroidal anti-inflammatory drug	157	0.2%
Vedolizumab	Integrin receptor antagonist	156	0.3%
Levetiracetam	—	151	0.3%
Clopidogrel	P2Y12 platelet inhibitor	146	0.5%
Tremfya	Interleukin-23 antagonist	144	0.4%
Paracetamol	—	136	0.5%
Quetiapine	Atypical antipsychotic	135	0.3%
Depo-Provera	Progestin	133	0.7%
Latuda	Atypical antipsychotic	131	0.8%

Drugs with a page on this site, ordered by the number of their reports recording this term. The last column is the term's share within that drug's own reports, against 0.1% across the whole database. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

By pharmacologic class

Class	Reports with this term	Share of class reports	Median drug in class
Atypical antipsychotic	1,073	0.2%	0%
Angiotensin 2 receptor blocker	888	0.4%	0%
Nonsteroidal anti-inflammatory drug	828	0.2%	0%
PCSK9 inhibitor	651	0.4%	0%
Gonadotropin releasing hormone receptor agonist	601	1%	0.1%
Corticosteroid	455	0.1%	0%
Central nervous system stimulant	443	0.4%	0%
Tumor necrosis factor blocker	378	0%	0%
Benzodiazepine	347	0.1%	0.1%
Opioid agonist	337	0%	0%

Classes ordered by count. Class shares follow the class's overall report volume as much as anything else.

Patients in these reports

Patient age

Under 21.1%216

2 to 113.2%631

12 to 172%402

18 to 4414.5%2,847

45 to 6414.5%2,854

65 to 7410.4%2,057

75 and over11.1%2,188

Age not given43.2%8,502

Patient sex

Female51%10,049

Male32.7%6,437

Not given16.3%3,211

Grey bar: all 20,646,523 reports in the database. 71.1% of these reports give the United States as the country.

Questions about "Product administration error"

What does "Product administration error" mean in an adverse event report?

In plain language: a mistake in giving the product. It is a MedDRA preferred term, the dictionary FDA uses to code what a reporter described. The report's own description is not published by openFDA and is not shown here.

How many reports record product administration error?

19,697 reports through June 2026 (0.1% of all reports), 2,081 of them in the latest 12 months.

Which drugs appear most often in these reports?

Makena (969), Repatha (642), Oxervate (616), Eligard (559) and Humira (546). Drugs with many reports overall lead almost every term's list. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Does a drug appearing here mean it was responsible for this reaction?

No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

I have this symptom. What should I do?

This site cannot assess anyone. A pharmacist or clinician can; for an emergency, call the local emergency number. Nothing on this page is medical advice.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. Terms are pooled across spelling and capitalisation variants of one MedDRA preferred term. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.